Gary D. Glick is an accomplished biopharmaceutical executive and academic with extensive experience in leadership roles within the industry. Currently serving as Executive Chairman at CHARM Therapeutics and Founder and CEO at Odyssey Therapeutics, Glick has also held the position of Founder, CEO, and Chairman at IFM Therapeutics since 2015. Previously, Glick co-founded and led Scorpion Therapeutics and founded Lycera, where Glick served as Chief Scientific Officer. In academia, Glick was the Werner E. Bachmann Professor of Chemistry at the University of Michigan from 1990 to 2016. Glick's educational background includes a postdoctoral fellowship in Organic Chemistry from Harvard University and a PhD in Organic Chemistry from Columbia University, complemented by a BA in Chemistry from Rutgers University.